Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity

Background Psoriasis is a chronic immune‐mediated inflammatory skin disease associated with increase of some pro‐inflammatory mediators. We wanted to investigate whether there is a relationship between psoriasis and visfatin, fetuin‐A and pentraxin 3 (PTX3)—pro‐inflammatory mediators implicated in the development of insulin resistance (IR), metabolic syndrome, and atherosclerosis. Methods Visfatin, fetuin‐A, and PTX3 concentrations were measured in 45 patients with plaque‐type psoriasis and 45 healthy controls using enzyme‐linked immunosorbent assay (ELISA). Results Serum levels of visfatin, fetuin‐A, and PTX3 in patients with psoriasis were found to be higher than in healthy controls (P = 0.002, P = 0.009, P < 0.001, respectively). Psoriasis area and severity index (PASI) score correlated significantly with visfatin and fetuin‐A levels (P = 0.011, P = 0.040, respectively). There was a significant positive correlation between visfatin and fetuin‐A (P < 0.001). PTX3 levels were correlated positively with homeostasis model assessment (HOMA‐IR), insulin, triglyceride (TG), and very low density lipoprotein cholesterol (VLDL; P = 0.009, P = 0.007, P = 0.023, P = 0.024, respectively). Conclusions Increased serum visfatin, fetuin‐A, and PTX3 levels, and the presence of positive correlation between visfatin, fetuin‐A, and PASI score, probably reflect the inflammatory state and IR seen in psoriasis.